ArticleGastro hep advances2025
Effects of Oral Anticoagulant and Antiplatelet Agents on Performance of Multitarget Colorectal Cancer Screening Test.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The multitarget stool DNA (mt-sDNA) test is a noninvasive screening tool for colorectal cancer. We aimed to clarify the effects of antiplatelet and anticoagulant medications on the diagnostic performance of this test. Methods: We retrospectively identified patients undergoing mt-sDNA testing from Mayo Clinic sites across the US during a 5-year period. Participants with positive stool testing results and subsequent high-quality colonoscopy were included. Participants were grouped by medication use: antiplatelets, anticoagulants, both, or none of these medications. The primary outcomes were the effects on positive predictive value (PPV) of the test for identifying advanced adenoma by antithrombotic use. Results: Of the 11,761 persons with a positive mt-sDNA test result, 8926 persons (age range, 45-91 years) underwent colonoscopy at our institution, of which 7750 were deemed high quality. Among these, 2435 patients were diagnosed with advanced adenomas, for a PPV of 31.4% for detecting advanced adenomas with the mt-sDNA test. The PPVs for advanced adenoma were 32.1% in nonantithrombotic users, 29.2% in antiplatelet users, 30.9% in anticoagulant users, and 31.7% in users of both medications. Additionally, among all patients with positive mt-sDNA testing and subsequent follow-up colonoscopy (n = 8926), colorectal cancer developed in 116 patients, for a notable 1.3% risk of cancer after positive test results and colonoscopy. Conclusion: In a large retrospective cohort in the US, the PPV of mt-sDNA testing for advanced adenomas was 31.4%. Use of antiplatelet or anticoagulant agents did not affect the PPV for detection of advanced adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.